Fannie Mae, Freddie Mac shares tumble after conservatorship comments
On Tuesday, H.C. Wainwright reaffirmed its positive stance on BioLife Solutions (NASDAQ:BLFS), maintaining a Buy rating and a $30.00 price target for the company’s shares. The decision follows a recent discussion with BioLife’s management, which led to an adjustment in the firm’s quarterly revenue projections for the year 2025. According to InvestingPro data, analysts’ targets range from $30 to $34, with two analysts recently revising earnings estimates upward for the upcoming period.
Analysts at H.C. Wainwright have updated their financial model for BioLife Solutions to reflect expected sequential quarter-over-quarter growth in 2025, excluding the impact of discontinued operations. This outlook is based on the anticipated performance compared to the revenue highs seen in the first and third quarters of 2024. Despite these adjustments, the full-year revenue projection remains set at $97.5 million. InvestingPro data shows the company’s strong revenue growth trajectory, with a projected 19% increase for FY2025.
It is important to note that the company’s management previously provided guidance for Cell Processing revenue to range between $86.5 million and $89.0 million in 2025. Additionally, the revenue guidance for evo and Thaw products was projected to be between $9.0 million and $10.0 million. H.C. Wainwright’s analysis points out that Product revenue on BioLife’s income statement includes both Cell Processing revenue and a portion of evo and Thaw revenue. The remaining part of evo and Thaw revenue is accounted for under Service revenue and Rental revenue categories.
The updated financial model and reaffirmed rating and price target by H.C. Wainwright suggest a steady outlook for BioLife Solutions. The firm’s analysts have expressed confidence in the company’s revenue growth trajectory, particularly in the absence of discontinued operations affecting the financials. BioLife Solutions continues to be seen as a solid investment by H.C. Wainwright, with a clear path to achieving its projected revenue targets. InvestingPro analysis reveals the company maintains strong financial health with a current ratio of 4.73 and operates with moderate debt levels. Get access to 6 more exclusive ProTips and comprehensive financial analysis through InvestingPro’s detailed research reports.
In other recent news, BioLife Solutions reported its first-quarter earnings for 2025, surpassing expectations with an earnings per share (EPS) of -$0.01, beating the forecast of -$0.05. The company’s revenue reached $23.9 million, exceeding the anticipated $21.6 million, marking a 30% year-over-year increase. BioLife Solutions also highlighted an improvement in its adjusted EBITDA margin to 24%, demonstrating enhanced operational efficiency. Additionally, the company reaffirmed its full-year revenue guidance of $95.5 million to $99 million, projecting 16-20% growth. BioLife’s recent acquisition of Panthera CryoSolutions is expected to bolster its biopreservation portfolio, although no substantial revenue from Panthera is anticipated in 2025. Analysts from Jefferies and KeyBanc inquired about the company’s strategic initiatives, including the integration of Panthera’s technology and pricing strategies. BioLife Solutions’ CEO emphasized the company’s robust market position and strategic focus on growth initiatives. These developments underscore BioLife Solutions’ strong performance and strategic direction for the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.